Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Phase 3 Enrolling by invitation 7 enrolled Neurocrine Biosciences

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.

Timeline

Start: 2024-04-24
Primary completion: 2028-04
Completion: 2028-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Valbenazine	Small molecule	—	Oral

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Summary

Timeline

Drugs

Indications